Stryker (SYK) Stock Forecast & Price Target

$350.26 -12.72 (-3.50%)

As of 02:30 PM Eastern

Stryker - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
4

Buy
16

Based on 20 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 4 have given a hold rating, and 16 have given a buy rating for SYK.

Consensus Price Target

$421.90
20.46% Upside

According to the 20 analysts' twelve-month price targets for Stryker, the average price target is $421.90. The highest price target for SYK is $450.00, while the lowest price target for SYK is $370.00. The average price target represents a forecasted upside of 20.46% from the current price of $350.26.

Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

SYK Analyst Ratings Over Time

Type	Current Forecast 4/10/24 to 4/10/25	1 Month Ago 3/11/24 to 3/11/25	3 Months Ago 1/11/24 to 1/10/25	1 Year Ago 4/11/23 to 4/10/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	17 Buy rating(s)	11 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$421.90	$421.90	$405.80	$335.27
Forecasted Upside	20.46% Upside	15.48% Upside	10.86% Upside	-3.40% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Stryker Stock vs. The Competition

Type	Stryker	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	16.09% Upside	16,158.95% Upside	24.79% Upside
News Sentiment Rating	Very Positive News See Recent SYK News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/21/2025	Needham & Company LLC 2 of 5 stars	Mike Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$442.00 ➝ $442.00	+18.28%
3/4/2025	The Goldman Sachs Group 3 of 5 stars		Set Target		$422.00	+12.41%
2/26/2025	Citigroup 2 of 5 stars	Joanne Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$450.00	+15.22%
2/18/2025	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Turkaly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
2/10/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$418.00 ➝ $443.00	+13.18%
2/3/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$450.00	+17.62%
1/30/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$409.00 ➝ $413.00	+5.06%
1/29/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$425.00 ➝ $435.00	+11.57%
1/29/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$427.00 ➝ $435.00	+12.11%
1/29/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$420.00 ➝ $445.00	+12.68%
Get the Latest News and Ratings for SYK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter.
1/29/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$400.00 ➝ $440.00	+11.41%
1/29/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kyle Rose Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$420.00 ➝ $435.00	+10.15%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$370.00 ➝ $445.00	+13.48%
10/30/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$383.00 ➝ $394.00	+8.50%
10/30/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$380.00 ➝ $420.00	+17.04%
10/30/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$366.00 ➝ $370.00	+2.61%
10/30/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$380.00 ➝ $384.00	+6.50%
10/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$378.00 ➝ $405.00	+12.73%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$405.00	+11.64%
5/1/2024	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$348.00 ➝ $405.00	+24.47%
4/11/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$365.00 ➝ $400.00	+15.82%
9/5/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$310.00 ➝ $315.00	+10.74%
5/2/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$260.00 ➝ $292.00	-0.78%
5/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$320.00 ➝ $345.00	+15.04%
4/23/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$275.00 ➝ $336.00	+10.69%
4/17/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$290.00 ➝ $312.00	+6.94%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:30 PM ET.

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 9, 2025. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

The company has a solid dividend yield of 0.97%, providing a steady income stream for investors. This yield is calculated based on the annualized dividend of $3.36 per share, which is attractive for income-focused investors.
Stryker Co. has a relatively low dividend payout ratio of 43.30%, indicating that it retains a significant portion of its earnings for reinvestment and growth, which can lead to long-term capital appreciation.
Recent insider trading activity shows confidence in the company, with Director Ronda E. Stryker selling a substantial number of shares but still retaining a significant ownership stake, valued at approximately $1.43 billion. This suggests that insiders believe in the company's future potential.
The current stock price is around $392.24, reflecting strong market performance and investor interest, which can be a positive indicator for potential growth.
Stryker Co. operates in the medical technology sector, which is expected to grow due to increasing healthcare demands and advancements in medical devices, positioning the company well for future success.

Stryker
Bear Case

Investors should be bearish about investing in Stryker Co. for these reasons:

Insider sales, such as the recent transaction by Director Allan C. Golston, where he sold 2,458 shares, may raise concerns about the company's short-term outlook, as it could indicate a lack of confidence in immediate performance.
The medical technology sector can be highly competitive and subject to regulatory changes, which may impact Stryker Co.'s market position and profitability.
With corporate insiders owning only 5.50% of the company's stock, there may be less alignment between management and shareholder interests, potentially leading to decisions that do not prioritize shareholder value.
The stock's high price point may deter new investors, as it requires a significant capital investment to acquire shares, which could limit the stock's liquidity and market appeal.
Market volatility and economic uncertainties can affect stock performance, and Stryker Co. is not immune to broader market trends that could negatively impact its stock price.

SYK Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $421.90, with a high forecast of $450.00 and a low forecast of $370.00.
: 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last twelve months. There are currently 4 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SYK shares.
: According to analysts, Stryker's stock has a predicted upside of 20.46% based on their 12-month stock forecasts.
: Stryker has been rated by research analysts at Argus, Barclays, Canaccord Genuity Group, Citigroup, JMP Securities, JPMorgan Chase & Co., Needham & Company LLC, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Stryker less than other "medical" companies. The consensus rating score for Stryker is 2.80 while the average consensus rating score for "medical" companies is 2.82. Learn more on how SYK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:SYK) was last updated on 4/10/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Stock Forecast & Price Target